Researchers from the Helmholtz Zentrum München (HMGU) and the Technische Universität München (TUM), together with scientists in the USA, discovered that the hormone can act on the receptors in insulin-stimulating hormones GLP-1 and GIP, helping to reduce weight and improve blood sugar in patients.
he three most vital and effective elements of wound therapy: moisture, antibiotics, and oxygen have been combined and can be efficiently delivered by a new system called the VHT® Wound Treatment System, developed and marketed by Cure Care, Inc.
A recent study from the University Group Diabetes Program (UDGP) reports that a drug often combined with metformin (also known as Glucophage) actually increases a person with type 2 diabetes’ risk of death.
An insulin pill, long desired by diabetes doctors and patients but abandoned as not physically viable, could be available by the end of this decade as a tiny Israeli company races a Danish pharmaceutical giant to be first with what could be a multibillion-dollar product.
The drug is intended to help people who suffer from diabetic foot ulcers, and, if successful, could help the estimated 70,000 Americans who undergo an amputation due to diabetes complications each year, Garcia said in an interview with The Associated Press on Tuesday.
This week, Wil tackles a question about those dreaded side effects we can experience from certain diabetes medications. His takeaway: Make sure you don’t close your eyes to the possibilities
Many people with type 2 diabetes are familiar with Byetta, a drug that helps raise their insulin levels. But a new study in the journal Diabetes Care suggests that the drug, known generically as exenatide, might have a role to play for people with type 1 diabetes as well.
There is a common misperception that older drugs, particularly those that have been on the market for decades, are safer than new drugs. The general belief is that, because they have been prescribed by thousands of doctors to millions of patients around the world, these old drugs are well characterized and well understood.
A new systematic review of published studies suggests when prescribing antidepressant medication, clinicians should be extra aware that they are linked to raised risk for type 2 diabetes, although the study does not suggest the drugs are the direct cause.
The investigational glucagon-like peptide-1, once-weekly dulaglutide, appears to control diabetes in relatively recently diagnosed patients better than daily metformin monotherapy, researchers reported here.
Alefacept (sold as Amevive) was used to treat the skin disorder psoriasis in the US before it was withdrawn by its manufacturer in 2011. The drug was never approved for the European drug market.Psoriasis, like type 1 diabetes, is an autoimmune disorder that occurs when the immune system attacks healthy skin cells.
According to Bayer, which co-developed the drug along with Regeneron, the drug VEGF Trap-Eye, also known as Eylea, has reached goals established by the companies during year-long, Phase 3 trials.
The drug of choice to treat type 2 diabetes may have uses beyond the treatment of diabetes alone, according to the results a new study.
Here’s a look at a few type 2 drugs researchers are working on. Some are close to market while others will take a few years longer before they can pass tests that establish their marketability.
According to new research from Australia, the oral diabetes medicine metformin is linked to impaired brain function, but supplementation with vitamin B12 may reduce some of the cognitive effects
Diabetes pills known as DPP-4 therapies got a mixed safety report on Monday as studies showed they did not raise the risk of heart attacks but might be linked to heart failure, where the heart fails to pump blood adequately.
Children who took the drugs—whose brand names include Risperdal, Seroquel, Abilify and Zyprexa—had a three-fold increased risk of Type 2 diabetes compared to children with the same conditions who took other medications.
Kevan Herold, MD, of Yale University, and colleagues reported that the GLP-1 agonist exenatide (Byetta) may have metabolic effects on patients with type 1 diabetes.
Novo Nordisk’s new drug IDegLira is a fixed-ratio combination of insulin degludec and the glucagonlike perptide-1 (GLP-1) agonist liraglutide. It combines the effects of insulin degludec and liraglutide in a once daily injection.
Among women with gestational diabetes mellitus, those receiving metformin achieve lower mean glucose levels compared with those receiving insulin, but some require supplemental insulin therapy, according to research published in the July issue of the American Journal of Obstetrics & Gynecology